Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This trial is evaluating the use of oral Everolimus to determine if there is a reduction in
the size of the disfiguring cutaneous lesions in patients with Neurofibromatosis 1 over a 6
month period. The evaluation will be done by 3D photography measuring volume with the LIFEVIZ
Micro system.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston